Press release

WISE EQUITY INVESTS IN E-PHARMA TRENTO, EUROPEAN LEADER IN EFFERVESCENT TECHNOLOGIES FOR CONSUMER HEALTH

The Wisequity VI fund joins Unifarm as a shareholder in the Trento-based company, a specialist in the development and contract manufacturing of effervescent and soluble dosage forms for the pharmaceutical and nutraceutical markets.

This is the eighth investment by Wisequity VI, intended to support the Company in its organic growth, its international expansion and the further strengthening of its R&D capabilities.

Milan, Trento, August 7, 2026 – **Wise Equity**, as managing company of the fund Wisequity VI, and **Unifarm S.p.A.** announce the signing of a binding agreement for the investment of Wisequity VI in the share capital of **E-Pharma Trento S.p.A.**, with the aim of supporting the next phase of growth of the Company and of further strengthening its position as a European benchmark in the sector.

Under the agreement, Wisequity VI will acquire a majority stake in E-Pharma, with Unifarm retaining a significant shareholding in the Company.

Founded in Trento in 1993, E-Pharma is a contract development and manufacturing organization (CDMO) specialising in effervescent and soluble technologies, serving both the Consumer Health pharmaceutical market and the nutraceutical one. The Company covers the entire value chain – from formulation R&D and regulatory dossier management through to industrial-scale manufacturing – from two plants in Trento, dedicated respectively to pharmaceuticals and to food supplements, with a combined capacity of around 900 million units a year. Its portfolio spans effervescent tablets and granules, soluble powders and orodispersible forms, which lie behind some of the best-known over-the-counter brands sold in Italian and European pharmacies by some of the leading Italian and international pharmaceutical groups. The Company closed 2025 with revenues of more than €55 million, around 45% of which generated outside Italy.

Alongside its long-standing pharmaceutical business, E-Pharma has built a growing presence in nutraceuticals, which today accounts for roughly one third of revenues. This is a fast-growing market in which effervescent and soluble forms are still comparatively rare, and where the Company can apply the formulation know-how, quality standards and manufacturing processes developed on the pharmaceutical side: a distinctive combination which represents one of the main pillars of growth for the years ahead.

The shared industrial plan rests on a proactive commercial approach in Italian nutraceuticals, on widening the coverage of the main European markets and on strengthening R&D activities, long one of the Company's hallmarks, both through new projects jointly developed with customers and proprietary ones. Equally central to the plan are the Company's people and roots in Trentino: the expertise built over more than thirty years at the Trento sites is one of E-Pharma's most valuable assets. Looking further ahead, targeted acquisitions are also conceivable to broaden the range of technologies available and to extend the international manufacturing footprint.

Paolo Cainelli, Chairman of Unifarm, said: "E-Pharma is an industrial heritage and a wealth of expertise that Unifarm has helped to build and develop over more than thirty years of activity. Wise Equity's entry is a strategic step, intended to support a new phase of growth for the Company by making available further resources, expertise and investment capacity. For Unifarm, E-Pharma will not only continue but strengthen its role as a strategic industrial partner: the Company's growth path will further increase its value, widening the scope for collaboration and mutual development. In line with this vision, Unifarm will continue to invest in E-Pharma's development, retaining a significant shareholding in the Company and working alongside Wise Equity to deliver an industrial project geared to growth, innovation and long-term value creation."

Stefano Ghetti, Senior Partner of Wise Equity, who led the transaction together with **Ascanio Recchi**, Investment Manager, commented: "E-Pharma dominates a technological niche in which, across the whole of Europe, very few players are genuinely equipped to compete: a position that is hard to build and just as hard to attack. This is precisely the kind of company Wise Equity invests in – a solid leadership in a specialised segment, a strong export orientation and real room to grow, particularly in nutraceuticals. We are delighted to be starting out on this path alongside Unifarm and a first-class management team, with the ambition of guiding the Company through what we believe could be the most significant phase of growth in its history."

DEAL ADVISORS

Wise Equity was advised by:

- Simmons & Simmons for legal due diligence and contractual matters, with Andrea Accornero, Paolo Guarneri, Ida Montanaro, Alice Barlera, and Anna De Marco;
- Finerre as M&A advisor, with Ermanno Restano.
- KPMG for financial due diligence, with Matteo Ennio and Giulia Panella
- Deloitte STP for tax due diligence, with Giorgio Orlandini, Francesco Maria Paggini and Alessandro Siano;
- ERM for ESG/EHS due diligence, with Giovanni Aquaro, Anna Galbiati, Sebastian Felipe Prieto and Isotta Bernabei;

Unifarm and E-Pharma were advised by:

- Deutsche Bank as M&A advisor, with Marco Gasparin, Diego Dessi, and Francesco De Poli;

- Studio Scozzi Dottori Commercialisti as tax and financial advisor, with Naming Partner Maurizio Scozzi and Director Anna Postal;
- Valli-Mancuso e Associati as legal advisor, with Partner Marcello Mancuso.

***

About E-Pharma Trento

E-Pharma Trento S.p.A., founded in 1993 and based in Trento, is a contract development and manufacturing organization specialising in advanced solid oral dosage forms, with a particular focus on effervescent and soluble technologies.

About Unifarm

Unifarm S.p.A. is a holding company active in pharmaceutical wholesale distribution in Trentino, Alto Adige, Veneto, Sardinia, Liguria and Lombardy owned by around 800 pharmacists.

About Wise Equity

Wise Equity is an investment management company focused on closed-end funds investing in small and medium-sized Italian companies. The funds managed by Wise Equity typically carry out leveraged buyout and development capital operations in companies that hold leading positions in their respective niches, with two primary objectives: to increase critical mass – including through build-up operations – in order to improve competitiveness and profitability, and to foster international development. Wise Equity currently manages three funds:

- Wisequity IV, with subscribed capital of €215 million, invested in eight companies, seven of which have been fully realized;
- Wisequity V, launched in July 2019 with an allocation of €260 million, invested in eight companies, with two completed exits;
- Wisequity VI, launched in June 2023 with total commitments of €400 million, partially deployed across six investments.

***

FOR FURTHER INFORMATION

Press Office – Wise Equity
Close to Media – founded by Elisabetta Neuhoff
wise@closetomedia.it

Adriana Liguori, adriana.liguori@closetomedia.it | mob. +39 345.1778974
Elena Gioia, elena.gioia@closetomedia.it | mob. +39 337.1064754